Ligand Pharmaceuticals (LGND) Gross Profit (2011 - 2026)

Ligand Pharmaceuticals has disclosed Gross Profit across 16 years of filings, most recently posting $48.4 million for Q1 2026.

• Gross Profit for Q1 2026 came in at $48.4 million, up 19.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $261.5 million (up 55.24% YoY), and the FY2025 annual result was $253.5 million, up 62.46% from the prior year.
• Gross Profit came in at $48.4 million for Q1 2026 at Ligand Pharmaceuticals, down from $56.7 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $111.7 million in Q3 2025 to a low of $24.7 million in Q2 2023.
• The 5-year median for Gross Profit is $40.0 million (2024), against an average of $42.5 million.
• Across the five-year window, Gross Profit tumbled 35.24% in 2022 and soared 126.2% in 2025, its largest moves.
• Ligand Pharmaceuticals' Gross Profit stood at $28.8 million in 2022, then fell by 8.02% to $26.5 million in 2023, then jumped by 51.08% to $40.0 million in 2024, then jumped by 41.77% to $56.7 million in 2025, then retreated by 14.51% to $48.4 million in 2026.
• The last three Gross Profit figures came in at $48.4 million (Q1 2026), $56.7 million (Q4 2025), and $111.7 million (Q3 2025), per Business Quant data.